Two new treatment options for aggressive prostate cancer have shown significant promise in a Phase 3 clinical trial led by Cedars-Sinai Cancer investigators.
The treatments improved survival rates without disease progression, potentially changing future medical practices.
The study and its impact
The international study, published in the New England Journal of Medicine, involved 1,068 prostate cancer patients from 17 countries.
Stephen Freedland, MD, the study's lead author, stated that if these treatments gain FDA approval, the results will be "practice-changing."
One treatment combined androgen deprivation therapy (ADT) with a medication called enzalutamide, reducing the risk of metastasis or death by 58% compared to ADT alone.
The other treatment used enzalutamide alone, reducing the risk by 37%.
The study was funded by Pfizer and Astellas Pharma, the co-developers of enzalutamide. The next step is to seek FDA approval for these promising therapies.